TABLE 2.
Cell cycle analysis of A431 cells treated with combinations of gefitinib and NVP-ADW742
Data are the average of two independent experiments.
|
Treatment |
Percentage of viable
cellsa |
Percentage of total
cellsb |
||
|---|---|---|---|---|
| G1 | S | G2 | Sub-G0 | |
| % | % | % | % | |
| 24 h | ||||
| None | 50.3 | 40.2 | 9.5 | 0.7 |
| DMSO | 51.7 | 38.4 | 9.9 | 0.6 |
| Gefitinib 3 μm | 65.7 | 28.0 | 6.3 | 1.6 |
| NVP-ADW742 3 μm | 59.5 | 30.5 | 10.0 | 0.6 |
|
Gefitinib + NVP-ADW742
|
87.5
|
3.5
|
9.0
|
9.9
|
| 48 h | ||||
| None | 48.4 | 42.1 | 9.5 | 0.7 |
| DMSO | 44.9 | 49.3 | 5.8 | 0.7 |
| Gefitinib 3 μm | 81.7 | 11.6 | 6.7 | 2.1 |
| NVP-ADW742 3 μm | 56.3 | 35.6 | 8.1 | 0.9 |
| Gefitinib + NVP-ADW742 | 91.1 | 3.8 | 5.0 | 25.1 |
a
Data are expressed as the percentage of viable cells.
b
Data are expressed as the percentage of the total cell count.